



Daiichi-Sankyo

TSE : 4568

# Reference Data

(Consolidated Financial Results for 3Q FY2008)

[1] Summary of Income Statement	P1
[2] Currency Rate	P3
[3] Sales of Global Products	P3
[4] Overseas Sales	P4
[5] Consolidated Segment Information – Operating Segment	P5
[6] Consolidated Segment Information – Geographic Segment	P5
[7] Status of Major Companies	P6
[8] Number of Employees	P10
[9] Consolidated Balance Sheets	P11
[10] Consolidated Statements of Cash Flows	P13
[11] R&D Pipeline	P14

<Historical Data>

Daiichi Sankyo is currently conducting purchase price allocation of our investment in Ranbaxy Laboratories Limited based on fair value appraisal which will form the basis of the valuations included in our audited full-year FY2008 financial results.

Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value.

# 1. Summary of Income Statement

< 1 Daiichi Sankyo Group - Consolidated >

(Billions of yen)

	FY2008 Results					
	3Q	Progress of 2nd half Forecast (Jan.)		YoY Changes	1-3Q	YoY Changes
Net sales	<-12.2> 100.0	221.3	49.9%	-30.8	<-9.8> 100.0	627.6 -68.2
Operating income	<-42.0> 16.5	36.4	94.9%	-26.4	<-37.5> 15.6	98.1 -58.7
Ordinary income	<-48.7> 15.2	33.5	358.3%	-31.8	<-43.9> 14.8	93.2 -72.9
Net income	<- > -	-331.8	-	-368.0	<- > -	-297.8 -394.2

< 2 Impact of the consolidation of Ranbaxy's financial results >

(Billions of yen)

	FY2008 Results					
	3Q	Progress of 2nd half Forecast (Jan.)		YoY Changes	1-3Q	YoY Changes
Net sales						
Operating income						
Ordinary income						
Net income						

\* Ranbaxy Laboratories Limited became a subsidiary of Daiichi Sankyo as of October 1st, 2008.

4Q (Oct.-Dec.) financial results of Ranbaxy will be consolidated in the 4Q (Jan.-Mar.) results of DaiichiSankyo.

< 3 Goodwill amortization of Ranbaxy >

	FY2008 Results		
	3Q	1-3Q	YoY Changes
<amortization>			
SG&A	5.5	5.5	-
Operating income	-5.5	-5.5	-
<one-time write-off>			
Extraordinary losses	354.0	354.0	-
Net income	-359.5	-359.5	-

< Performance excluding the impact of Ranbaxy combined in Daiichi Sankyo Group (1-2-3) >

(Billions of yen)

	FY2008 Results					Real term comparison (Special factors* excluded)		Details FY07 1-3Q Results ==> FY08 1-3Q Results	
	3Q	Progress of 2nd half Forecast (Jan.)		YoY Changes	1-3Q	YoY Changes	3Q YoY changes		1-3Q YoY Changes
Net sales	<-12.2> 100.0	221.3	54.8%	-30.8	<-9.8> 100.0	627.6 -68.2	<-9.0> -21.8	<-4.4> -28.7	Commercial rights transfer (Coversyl, Zantac, etc.): -11.0 Loss from currency fluctuation: -28.0
Cost of sales	24.0	53.1	54.0%	-15.4	24.0	150.8 -31.0	-7.3	-4.7	+0.3pt: Change in business scheme of Panalidine +1.0pt NHI price revision +0.9pt Product mix, cost reduction
Selling, general and administrative expenses	57.0	126.2	49.1%	5.5	59.5	373.3 16.0	6.6	28.2	
Research and development expenses	21.2	46.8	50.0%	8.1	20.6	129.2 12.1	8.3	13.2	Increase in in-license costs +5.0 FY07 Denosumab 2.5 FY08 ArQule 7.5 Increase due to progress in development of projects including Denosumab, CS-8958
Other expenses	35.9	79.4	48.6%	-2.6	38.9	244.1 3.8	-1.7	15.0	Increase in personnel cost (Japan): +5.5 (temporarily decreased in FY07 due to the integration of retirement benefit and pension plans) Intensive investment in U.S./EU: +9.6
Operating income	<-33.3> 18.9	41.9	86.7%	-20.9	<-34.0> 16.5	103.5 -53.2	<-33.5> -21.1	<-33.5> -52.2	
Non-operating income		3.0	62.3%	-0.4		9.2 -3.0	-0.4	-2.7	Decrease in funds applied
Non-operating expenses		5.9	75.1%	5.0		14.0 11.1	5.0	11.2	Loss on revaluation of synthetic stock options in DSI in the US: +3.2 Loss from currency fluctuation: +6.5 Valuation loss of European subsidiary's asset Interest on bank loans borrowed for the acquisition of Ranbaxy's shares
Ordinary income	<-40.3> 17.6	39.0	86.1%	-26.3	<-40.6> 15.7	98.7 -67.4	<-40.4> -26.5	<-40.1> -66.1	
Extraordinary gains		1.8	68.5%	1.7		2.7 -1.4	1.7	0.2	
Extraordinary losses		3.4	39.2%	1.1		7.3 -1.7	1.1	-1.7	FY2007-Loss on business integration/restructuring: 4.6
Income before income taxes and minority interests	16.9	37.5	95.1%	-25.7	15.0	94.1 -67.1	-25.9	-64.2	
Net income	<-23.4> 12.5	27.7	106.4%	-8.5	<-36.0> 9.8	61.7 -34.7	<-28.5> -11.0	<-35.8> -34.3	

\* Figures of non-pharmaceutical subsidiaries spun off, and the impact of change in the accounting periods of EU subsidiaries are considered as special factors.

In order to compare the results in the real term, figures excluding such factors are shown as "Special Factors Excluded."

The operating results of non-pharmaceuticals was net sales of ¥25.4 billion and operating income of -¥0.9 billion in the first nine months of FY2007.

The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

< 1 Daiichi Sankyo Group - Consolidated >

(Billions of yen)

	FY2008 Forecast						
	2nd half		YoY Changes	Full Year		From Oct. Forecast	YoY Changes
Net sales	<1.7>			<-3.4>			
	100.0	443.7	7.3	100.0	850.0	10.0	-30.1
Operating income	<-39.0>			<-36.2>			
	8.7	38.4	-24.5	11.8	100.0	-20.0	-56.8
Ordinary income	<-86.3>			<-59.2>			
	2.1	9.4	-59.0	8.1	69.0	-44.0	-100.1
Net income	<->			<->			
	-	-350.0	-387.4	-	-316.0	-381.0	-413.7

< 2 Impact of the consolidation of Ranbaxy's financial results >

(Billions of yen)

	FY2008 Forecast (Ranbaxy Oct.-Dec. Forecast)						
	2nd half		YoY Changes	Full Year		From Oct. Forecast	YoY Changes
Net sales	100.0	40.0	-	100.0	40.0	-	-
Operating income	2.5	1.0	-	2.5	1.0	-	-
Ordinary income	-	-25.0	-	-	-25.0	-	-
Net income	-	-11.0	-	-	-11.0	-	-

Exchange Rate 1 INR = 2yen

< 3 Goodwill amortization of Ranbaxy >

	FY2008 Forecast			
	2nd half	Full Year	From Oct. Forecast	YoY Changes
<amortization>				
SG&A	11.0	11.0	11.0	-
Operating income	-11.0	-11.0	-11.0	-
<one-time write-off>				
Extraordinary losses	354.0	354.0	354.0	-
Net income	-365.0	-365.0	-365.0	-

< Performance excluding the impact of Ranbaxy combined in Daiichi Sankyo Group (1-2-3) >

(Billions of yen)

	FY2008 Forecast					Real term comparison (Special factors* excluded)		From Oct. Forecast	Details	
	2nd half		YoY Changes	Full Year		YoY Changes	2nd half YoY change			Full year YoY Change
Net sales	<-7.5>			<-8.0>			<-4.1>	<-2.9>		Loss from currency fluctuation: -7.0 OTC drugs: -4.0 Decrease due to change in schedule of Prasugrel (US), etc.
	100.0	403.7	-32.7	100.0	810.0	-70.1	-17.1	-24.0	-30.0	
Cost of sales	24.4	98.4	-23.0	24.2	196.0	-38.6	-9.7	-7.0	-9.0	Loss from currency fluctuation: -1.0
Selling, general and administrative expenses	63.6	256.9	4.8	62.2	504.0	15.3	6.6	28.2	-11.0	
Research and development expenses	23.2	93.7	8.5	21.7	176.0	12.5	8.8	13.6	-4.0	Loss from currency fluctuation: -2.0 Reduction of expenses other than development cost: -2.0
Other expenses	40.4	163.3	-3.7	40.5	328.0	2.8	-2.2	14.5	-7.0	Loss from currency fluctuation: -3.0 Decrease in marketing cost of Prasugrel (US) due to change in schedule, etc.
Operating income	<-23.1>			<-29.9>			<-22.4>	<-29.1>		
	12.0	48.4	-14.5	13.6	110.0	-46.8	-14.0	-45.1	-10.0	
Non-operating income		4.9	-3.4		11.0	-6.0	-3.4	-5.6	2.0	
Non-operating expenses		7.9	5.1		16.0	11.2	5.2	11.3	0.0	
Ordinary income	<-33.6>			<-37.9>			<-33.1>	<-37.2>		
	11.2	45.4	-23.0	13.0	105.0	-64.1	-22.5	-62.1	-8.0	
Extraordinary gains		2.7	-9.5		3.5	-12.6	-2.5	-3.9	-1.5	
Extraordinary losses		8.6	-3.1		12.5	-5.8	-1.6	-4.4	3.5	Loss from impairment of buildings, etc.
Income before income taxes and minority interests	9.8	39.4	-29.5	11.9	96.0	-70.9	-23.3	-61.6	-13.0	
Net income	<-30.4>			<-38.6>			<-31.2>	<-36.9>		
	6.4	26.0	-11.4	7.4	60.0	-37.7	-11.8	-35.1	-5.0	

The operating results of non-pharmaceuticals was net sales of ¥32.0 billion and operating income of -¥0.1 billion in FY2007.

The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

## 2. Currency Rate

	FY2007	FY2008			FY2008 Original Forecast	FY2008 Forecast	
	3Q YTD Results	3Q YTD Results	4Q Forecast	Full Year Forecast	Full Year	Annual impact of one yen change in currency rate	
Yen / USD (average)	117.3	102.8	90.0	99.6	100.0	Net Sales	¥2.1 billion
Yen / EUR (average)	161.2	150.7	120.0	143.0	155.0	Operating Income	¥0.3 billion
						Net Sales	¥0.5 billion
						Operating Income	-

## 3. Sales of Global Products

		FY2008 Results					FY2008 Forecast				YoY changes excluding fiscal year-end changes	
		3Q	Progress	YoY Changes	3Q YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes	3Q YTD	Full Year
<b>Olmesartan</b> <antihypertensive>	(area)	<6.6>			<7.6>		<9.1>	<8.7>			<12.4>	<11.8>
		<b>57.6</b>	<b>53.4%</b>	<b>3.6</b>	<b>162.2</b>	<b>11.5</b>	<b>107.9</b>	<b>212.5</b>	<b>-5.5</b>	<b>16.9</b>	<b>17.9</b>	<b>22.3</b>
Olmotec	JPN	<6.0>	18.7	52.3%	1.1	50.0	6.0	<13.6>	<24.0>	<21.4>		
Benicar / Benicar HCT	US	<7.5>	22.3	56.4%	-1.8	67.8	-0.8	<8.9>	<-3.3>			
AZOR	US	<39.6>	2.6	50.5%	0.7	6.4	4.5	<240.3>	<104.7>	<253.3>		
Olmotec / Olmetec Plus *	EU	<10.1>	9.1	48.5%	0.8	27.8	-2.8	<-9.1>	<-3.6>	<-10.3>	<14.9>	<5.9>
											3.6	2.1
Sevikar	EU	<->	1.4	55.6%	1.4	1.4	1.4	<->	<->			
Export / Asian & LA subsidiaries, etc		<62.0>	3.5	56.6%	1.3	8.8	3.2	<56.8>	<32.2>	<41.4>		
<b>Levofloxacin</b> <synthetic antibacterial>	(area)	<-19.8>			<-11.7>		<-10.1>	<-8.5>				
		<b>25.8</b>	<b>51.4%</b>	<b>-6.4</b>	<b>75.1</b>	<b>-10.0</b>	<b>50.2</b>	<b>99.5</b>	<b>-2.5</b>	<b>-9.2</b>		
Cravit	JPN	<-11.5>	13.7	54.0%	-1.8	33.3	-4.2	<-11.3>	<0.4>	<-5.0>		
Export, etc		<-36.8>	6.2	46.7%	-3.6	24.0	-3.5	<-12.6>	<-19.3>	<-8.9>		
Royalty		<-15.9>	4.1	49.8%	-0.8	12.1	-2.0	<-14.2>	<-20.3>	<-17.0>		
Asian subsidiaries		<-11.9>	1.8	53.3%	-0.2	5.7	-0.3	<-4.5>	<-13.0>	<-6.8>		
<b>Pravastatin</b> <antihyperlipidemic>	(area)	<-23.3>			<-21.7>		<-21.0>	<-20.9>			<-19.6>	<-19.2>
		<b>16.6</b>	<b>58.1%</b>	<b>-5.1</b>	<b>48.5</b>	<b>-13.4</b>	<b>28.6</b>	<b>60.5</b>	<b>0.0</b>	<b>-16.0</b>	<b>-11.8</b>	<b>-14.4</b>
Mevalotin	JPN	<-22.6>	14.1	57.9%	-4.1	40.7	-9.2	<-18.4>	<-18.4>	<-17.2>		
Export		<-54.0>	0.6	53.9%	-0.7	2.5	-1.8	<-42.4>	<-44.6>	<-40.1>		
European subsidiaries *		<1.2>	1.2	61.4%	0.0	3.2	-2.1	<-39.9>	<-21.0>	<-40.2>	<-14.3>	<-21.4>
											-0.5	-1.1
Asian & Latin American subsidiaries		<-25.4>	0.6	60.1%	-0.2	2.1	-0.3	<-12.0>	<-38.4>	<-21.8>		

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) in FY2007 was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. Three months results of Olmetec / Olmetec Plus and Pravastatin from Jan-07 to Mar-07 were ¥6.4 billion (€40 million) and ¥1.6 billion (€10 million), respectively.

## 4. Overseas Sales

Consolidated basis

(Billions of yen)

	FY2008 Results					FY2008 Forecast							
	3Q	Progress	YoY Changes	3Q YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes				
Overseas sales	<-9.3>	83.8	55.8%	-8.6	<-8.0>	258.5	-22.3	<17.7>	<-4.6>	200.3	375.0	30.0	16.4
Overseas sales ratio		37.9%		41.2%		45.1%	44.1%						

Overseas sales of Ranbaxy

(Billions of yen)

	FY2008 Forecast			
	2nd half	Full Year	From Oct. Forecast	YoY Changes
Overseas sales	40.0	40.0	-	-

\* Ranbaxy joined Daiichi Sankyo group as of October 1st, 2008.

Ranbaxy's fourth quarter (Oct-Dec) figures will be consolidated into Daiichi Sankyo's fourth quarter (Jan-Mar).

Overseas sales excluding Ranbaxy

(Billions of yen)

	FY2008 Results					FY2008 Forecast				YoY changes excluding special factors*	
	3Q	Progress	YoY Changes	3Q YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes	3Q YTD	Full Year
Overseas sales	<-9.3>	83.8	55.8%	-8.6	<-8.0>	258.5	-22.3	<-5.8>	<-6.6>	<-0.8>	<-1.0>
Overseas sales ratio		37.9%		41.2%		39.7%	41.4%			-2.0	-3.3
North America	<-15.1>	52.8	54.1%	-9.4	<-5.0>	164.7	-8.7	<-10.2>	<-4.7>	<-5.0>	<-4.7>
		52.8	54.1%	-9.4		164.7	-8.7			-8.6	-10.3
Europe	<12.9>	21.9	49.0%	2.5	<-11.2>	67.6	-8.5	<7.4>	<-8.1>	<9.1>	<7.4>
		21.9	49.0%	2.5		67.6	-8.5			5.6	6.2
Asia / Latin America, etc	<-15.4>	9.1	50.7%	-1.7	<-16.2>	26.2	-5.1	<-9.3>	<-13.0>	<3.9>	<2.4>
		9.1	50.7%	-1.7		26.2	-5.1			1.0	0.8

\* Daiichi Sankyo made certain non-pharmaceutical business independent of the group in FY2007.

The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months following a change in its fiscal year-end from December to March.

YoY changes excluding special factors column excludes sales of non-pharmaceutical business and extra three months sales of DSE in FY2007.

## 5. Consolidated Segment information - Operating Segment

(Billions of yen)

	FY2008 Results					
	3Q	YoY Changes		1-3Q	YoY Changes	
<b>Net Sales</b>	<b>&lt;-12.2&gt;</b>	<b>221.3</b>	<b>-30.8</b>	<b>&lt;-9.8&gt;</b>	<b>627.6</b>	<b>-68.2</b>
Pharmaceuticals	<-8.6>	220.5	-20.7	<-6.0>	625.0	-40.2
Domestic	<-9.3>	123.2	-12.6	<-6.3>	328.1	-22.1
Overseas *	<-6.1>	84.0	-5.5	<-5.7>	258.4	-15.7
OTC drugs	<-13.2>	13.2	-2.0	<-6.2>	37.2	-2.4
Other	<-93.0>	0.8	-10.2	<-91.5>	2.6	-28.0
<b>Operating income</b>	<b>&lt;-42.0&gt;</b>	<b>36.4</b>	<b>-26.4</b>	<b>&lt;-37.5&gt;</b>	<b>98.1</b>	<b>-58.7</b>
Pharmaceuticals	<-42.5>	35.9		<-38.5>	96.3	
Other	<45.8>	0.5		<->	1.7	

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) in FY2007 was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

## 6. Consolidated Segment information - Geographic Segment

(Billions of yen)

	FY2008 Results							
	3Q	YoY Changes		1-3Q	YoY Changes			
<b>Net Sales</b>	<b>&lt;-12.2&gt;</b>	<b>100.0</b>	<b>221.3</b>	<b>-30.8</b>	<b>&lt;-9.8&gt;</b>	<b>100.0</b>	<b>627.6</b>	<b>-68.2</b>
Japan	<-15.8>	68.4	151.4	-28.3	<-12.2>	65.5	417.1	-58.0
North America	<-10.0>	20.8	46.0	-5.1	<0.8>	22.6	141.9	1.1
Europe*	<24.8>	8.1	18.0	3.6	<-13.6>	8.2	51.7	-8.1
Asia / Latin America, etc	<-13.9>	2.7	5.9	-1.0	<-15.7>	2.7	17.0	-3.2
<b>Operating income</b>	<b>&lt;-42.0&gt;</b>	<b>36.4</b>	<b>-26.4</b>	<b>&lt;-37.5&gt;</b>	<b>98.1</b>	<b>-58.7</b>		
Japan		25.5				52.2		
North America		11.6				39.4		
Europe *		0.5				1.8		
Asia / Latin America, etc		-3.5				-2.4		

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) in FY2007 was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

## 7. Status of Major Companies

### 7-1. Daiichi Sankyo Co., Ltd.

(Billions of yen)

	FY2008 Results					FY2008 Forecast			
	3Q	Progress	YoY Changes	3Q YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes
Total net sales of ethical pharmaceuticals	<-8.9>			<-6.5>		<-0.7>	<-2.8>		
	120.1	56.0%	-11.8	320.5	-22.4	214.6	415.0	0.0	-12.1
Cardiovascular disease	<-8.8>			<-5.9>		<0.7>	<-1.7>		
	65.5	53.3%	-6.3	182.7	-11.4	122.8	240.0	0.0	-4.2
Olmetec <antihypertensive>	<6.0>			<13.6>		<24.0>	<21.4>		
	18.7	52.3%	1.1	50.0	6.0	35.7	67.0	-1.0	11.8
Calblock <antihypertensive>	<13.6>			<19.4>		<31.3>	<27.3>		
	3.4	48.4%	0.4	9.4	1.5	7.0	13.0	-1.0	2.8
Artist <antihypertensive>	<0.5>			<2.8>		<13.5>	<8.8>		
	6.0	50.1%	0.0	17.0	0.5	12.0	23.0	1.0	1.9
Mevalotin <antihyperlipidemic agent>	<-22.6>			<-18.4>		<-18.4>	<-17.2>		
	14.1	57.9%	-4.1	40.7	-9.2	24.4	51.0	0.0	-10.6
Kremezin <treatment for chronic renal failure>	<-0.5>			<2.3>		<22.1>	<13.0>		
	3.5	46.4%	0.0	9.9	0.2	7.6	14.0	0.0	1.6
Hanp <treatment for acute cardiac failure>	<-5.2>			<-5.6>		<-0.2>	<-2.8>		
	2.8	52.6%	-0.2	7.0	-0.4	5.3	9.5	0.0	-0.3
Livalo <antihyperlipidemic agent>	<8.1>			<10.4>		<43.6>	<28.3>		
	1.8	43.1%	0.1	4.7	0.4	4.1	7.0	-1.0	1.5
Sunrhythm <antiarrhythmic agent>	<-6.1>			<-4.5>		<2.3>	<-0.7>		
	3.2	53.1%	-0.2	9.2	-0.4	6.1	12.0	0.0	-0.1
Fastic <antidiabetic agent>	<-2.9>			<-1.2>		<32.2>	<15.8>		
	1.4	41.8%	0.0	4.0	-0.1	3.4	6.0	0.0	0.8
Infectious diseases / bone and joint diseases / immunological allergic diseases / urology	<-2.6>			<-2.4>		<2.2>	<0.1>		
	44.7	58.6%	-1.2	107.4	-2.7	76.3	139.0	0.0	0.2
Cravit <synthetic antibacterial agent>	<-11.5>			<-11.3>		<0.4>	<-5.0>		
	13.7	54.0%	-1.8	33.3	-4.2	25.4	45.0	0.0	-2.4
Loxonin <anti-inflammatory analgesic>	<17.1>			<15.9>		<28.5>	<22.0>		
	11.5	51.9%	1.7	30.4	4.2	22.1	41.0	1.0	7.4
Mobic <anti-inflammatory analgesic>	<-23.1>			<-17.7>		<11.3>	<-2.4>		
	2.2	40.6%	-0.7	6.8	-1.5	5.4	10.0	0.0	-0.2
Urief <treatment for dysuria>	<25.9>			<41.1>		<60.5>	<57.0>		
	2.1	43.3%	0.4	5.7	1.7	5.0	8.5	0.0	3.1
Zyrtec <antiallergic agent>	<-15.6>			<-18.8>		<-14.2>	<-16.9>		
	2.2	41.4%	-0.4	5.8	-1.3	5.4	9.0	0.0	-1.8
Contrast agents / cancer / gastric diseases	<-19.0>			<-18.4>		<-19.5>	<-18.8>		
	13.9	59.8%	-3.2	38.7	-8.7	23.2	48.0	0.0	-11.1
Omnipaque <contrast agent>	<-13.2>			<-10.2>		<-5.3>	<-6.9>		
	8.0	55.5%	-1.2	22.6	-2.6	14.4	29.0	0.0	-2.2
Topotecin <anticancer agent>	<-1.0>			<0.5>		<9.2>	<5.3>		
	1.7	51.1%	0.0	4.9	0.0	3.4	6.5	0.0	0.3





## 7-5. Daiichi Sankyo Europe GmbH

(Billions of yen)

	FY2008 Results					FY2008 Forecast			
	3Q	Progress	YoY Changes	3Q YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes
Daiichi Sankyo Europe GmbH (DSE)	<24.2>			<-13.6>		<14.3>	<-9.0>		
	<b>18.0</b>	<b>48.2%</b>	<b>3.5</b>	<b>51.7</b>	<b>-8.1</b>	<b>37.3</b>	<b>71.0</b>	<b>-1.0</b>	<b>-7.0</b>
mil €	<53.8>			<-7.6>		<42.4>	<2.2>		
	<b>136</b>	<b>47.0%</b>	<b>48</b>	<b>343</b>	<b>-28</b>	<b>289</b>	<b>496</b>	<b>-13</b>	<b>11</b>
Olmotec / Olmetec Plus <antihypertensive>	<10.1>			<-9.1>		<-3.6>	<-10.3>		
	9.1	48.5%	0.8	27.8	-2.8	18.8	37.5	1.5	-4.3
mil €	<37.5>			<-2.8>		<21.3>	<0.6>		
	70	47.3%	19	184	-5	148	262	7	2
Sevikar <antihypertensive>	<->			<->		<->	<->		
	14.0	55.6%	14.0	14.0	14.0	2.5	2.5	-1.5	25.0
mil €	<->			<->		<->	<->		
	9	52.8%	9	9	9	17	17	-11	17
Mevalotin <antihyperlipidemic agent>	<1.2>			<-39.9>		<-21.0>	<-40.2>		
	1.2	61.4%	0.0	3.2	-2.1	2.0	4.0	0.5	-2.7
mil €	<23.3>			<-35.7>		<-0.7>	<-32.9>		
	9	58.2%	2	21	-12	16	28	3	-14
Evista <treatment for osteoporosis>	<134.5>			<153.8>		<114.1>	<138.3>		
	3.0	53.0%	1.7	9.8	5.9	5.7	12.5	0.0	7.3
mil €	<195.4>			<171.5>		<174.9>	<167.4>		
	23	51.2%	16	65	41	46	87	-1	55

\* Following the change in fiscal year-end, FY2007 results for DSE, Olmetec / Olmetec Plus, Mevalotin and Evista are fifteen-month totals from Jan-07 to Mar-08.

Three-month results from Jan-07 to Mar-07 are ¥14.1 billion (€89 million), ¥6.4 billion (€40 million), ¥1.6 billion (€10 million), and ¥1.0 billion (€6 million), respectively.

## 7-5. Daiichi Sankyo Europe GmbH <excluding the effect of change in fiscal year-end>

(Billions of yen)

	FY2008 Results					FY2008 Forecast			
	3Q	Progress	YoY Changes	3Q YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes
Daiichi Sankyo Europe GmbH (DSE)	<24.2>			<13.1>		<14.3>	<11.2>		
	<b>18.0</b>	<b>48.2%</b>	<b>3.5</b>	<b>51.7</b>	<b>6.0</b>	<b>37.3</b>	<b>71.0</b>	<b>-1.0</b>	<b>7.1</b>
mil €	<53.8>			<21.4>		<42.4>	<24.9>		
	<b>136</b>	<b>47.0%</b>	<b>48</b>	<b>343</b>	<b>60</b>	<b>289</b>	<b>496</b>	<b>-13</b>	<b>99</b>
Olmotec / Olmetec Plus <antihypertensive>	<10.1>			<14.9>		<-3.6>	<5.9>		
	9.1	48.5%	0.8	27.8	3.6	18.8	37.5	1.5	2.1
mil €	<37.5>			<23.3>		<21.3>	<18.9>		
	70	47.3%	19	184	35	148	262	7	42
Sevikar <antihypertensive>	<->			<->		<->	<->		
	1.4	55.6%	1.4	1.4	1.4	2.5	2.5	-1.5	2.5
mil €	<->			<->		<->	<->		
	9	52.8%	9	9	9	17	17	-11	17
Mevalotin <antihyperlipidemic agent>	<1.2>			<-14.3>		<-21.0>	<-21.4>		
	1.2	61.4%	0.0	3.2	-0.5	2.0	4.0	0.5	-1.1
mil €	<23.3>			<-7.9>		<-0.7>	<-11.6>		
	9	58.2%	2	21	-2	16	28	3	-4
Evista <treatment for osteoporosis>	<134.5>			<239.2>		<114.1>	<192.6>		
	3.0	53.0%	1.7	9.8	6.9	5.7	12.5	0.0	8.2
mil €	<195.4>			<264.2>		<174.9>	<228.8>		
	23	51.2%	16	65	47	46	87	-1	61

## 7-6. Asia, South and Central America (ASCA)

### 1) Net Sales by Companies

	FY2008 Results					FY2008 Forecast			
	3Q	Progress	YoY Changes	3Q YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes
<b>ASCA Total</b>	<b>&lt;14.3&gt;</b>	<b>5.9</b>	<b>50.0%</b>	<b>0.7</b>	<b>&lt;12.5&gt;</b>	<b>&lt;6.6&gt;</b>	<b>&lt;9.0&gt;</b>		
						<b>11.8</b>	<b>22.9</b>	<b>-10.0</b>	<b>1.9</b>
Daiichi Pharmaceutical (Beijing) Co., Ltd.	<11.4>	1.1	52.8%	0.1	<7.0>	<-2.4>	<0.9>		
						2.1	4.1	-1.0	0.0
Shanghai Sankyo Pharmaceuticals Co., Ltd.	<62.4>	1.1	49.5%	0.4	<52.8>	<86.1>	<67.0>		
						2.2	3.8	1.0	1.5
Daiichi Sankyo Korea Co., Ltd.	<-35.5>	0.6	56.4%	-0.3	<-10.2>	<-39.1>	<-17.8>		
						1.0	2.8	-7.0	-0.6
Daiichi Sankyo (Thailand) Ltd.	<-3.3>	0.2	47.6%	0.0	<3.5>	<-6.0>	<0.1>		
						0.4	0.8	0.0	0.0
Daiichi Sankyo Taiwan Ltd.	<-9.0>	0.8	50.4%	-0.1	<-2.0>	<-11.5>	<-4.9>		
						1.6	3.5	-4.0	-0.2
Daiichi Sankyo Brasil Farmacéutica Ltda.	<38.7>	1.4	51.0%	0.4	<22.1>	<14.0>	<13.7>		
						2.8	5.0	0.0	0.6
Daiichi Sankyo Venezuela, S.A.	<40.5>	0.7	42.1%	0.2	<24.5>	<21.2>	<19.1>		
						1.7	2.8	1.0	0.4

### 2) Sales of Major Products

	FY2008 Results					FY2008 Forecast			
	3Q	Progress	YoY Changes	3Q YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes
Olmesartan	<98.0>	2.1	50.4%	1.0	<94.0>	<61.5>	<73.4>		
						4.1	7.3	-0.2	3.1
Levofloxacin	<-11.9>	1.8	53.3%	-0.2	<-4.5>	<-13.0>	<-6.8>		
						3.4	7.3	-0.7	-0.5
Pravastatin	<-25.4>	0.6	60.1%	-0.2	<-12.0>	<-38.4>	<-21.8>		
						1.0	2.5	-0.5	-0.7

## 7-7. Ranbaxy Laboratories Limited

	FY2008 Forecast	
	2nd half	Full Year
Ranbaxy Laboratories Limited	<->	<->
	<b>40.0</b>	<b>40.0</b>
mil INR	<->	<->
	<b>200</b>	<b>200</b>

\* Ranbaxy joined Daiichi Sankyo group as of October 1st, 2008.

Ranbaxy's fourth quarter (Oct-Dec) figures will be consolidated into Daiichi Sankyo's fourth quarter (Jan-Mar).

## 8. Number of Employees

	FY2007	FY2008	
	Mar-08	Sep-08	Dec-08*
Total number of Employees	15,349	16,237	28,827
Japan	9,048	9,096	9,164
Overseas	6,301	7,141	19,663

	FY2007		FY2008			
	Mar-08	MRs	Sep-08	MRs	Dec-08*	MRs
Total number of Employees	15,349		16,237		28,827	
<Japan>						
Daiichi Sankyo Co., Ltd. (DS)	5,925	2,400	6,007	2,400	5,985	2,400
Daiichi Sankyo Healthcare Co., Ltd (DSHC)	396	150	401	150	402	150
<US>						
Daiichi Sankyo, Inc. (DSI)	2,446	1,550	2,856	1,810	2,873	1,820
Luitpold Pharmaceuticals, Inc. (LPI)	498	90	497	90	500	83
<Europe>						
Daiichi Sankyo Europe GmbH (DSE)	1,776	830	2,031	1,020	2,137	1,100
<Asia / Latin America>						
Daiichi Pharmaceutical (Beijing) Co., Ltd. (DPP)	443	143	470	164	461	161
Shanghai Sankyo Pharmaceuticals Co., Ltd. (SSP)	456	196	486	201	491	198
Daiichi Sankyo Hong Kong Ltd. (DSHK)	7	-	7	-	7	-
Daiichi Sankyo Korea Co., Ltd. (DSKR)	89	51	89	48	90	47
Daiichi Sankyo (Thailand) Ltd. (DSTH)	46	18	38	13	43	18
Daiichi Sankyo Taiwan Ltd. (DSTW)	150	65	159	69	161	67
Daiichi Sankyo Brasil Farmacéutica Ltda. (DSBR)	266	118	288	116	293	115
Daiichi Sankyo Venezuela, S.A. (DSVE)	123	70	128	61	140	80

	FY2007	FY2008	
	Mar-08	Sep-08	Dec-08*
Ranbaxy Laboratories Limited	-	-	Approx. 12,000

\* For overseas subsidiaries with different fiscal year-ends, figures as of Sep-08 are shown

## 9. Consolidated Balance Sheets

<Assets>

(Billions of yen)

	2008.3.31		2008.12.31		Change	Details
		%		%		
<b>Current assets</b>	<b>926.5</b>	<b>62.3%</b>	<b>823.8</b>	<b>55.7%</b>	<b>-102.7</b>	
Cash and time deposits	47.3		160.8		113.4	Liquidity on hand (current deposits + marketable securities + investment securities)
Trade notes and accounts receivable	167.0		245.4		78.4	Total ¥385.8 billion (¥276.1 billion from the end of fiscal 2007)
Marketable securities	526.8		165.4		-361.4	<Breakdown>
Inventories	98.2		143.6		45.4	¥ +122.6 billion by consolidation of Ranbaxy
Deferred tax assets	52.7		71.5		18.8	¥ -53.3 billion by dividends
Other current assets	34.9		46.3		11.5	¥ -45.8 billion by share buybacks
Allowance for doubtful accounts	-0.3		-9.1		-8.8	¥ -26.8 billion for the acquisition of U3 Pharma AG
						¥ -488.3 billion for the acquisition of Ranbaxy's share
						¥ +240.0 billion from borrowings
						Payment of account payable
<b>Non-current assets</b>	<b>561.4</b>	<b>37.7%</b>	<b>655.9</b>	<b>44.3%</b>	<b>94.5</b>	
Property, plant and equipment	221.3	14.9%	252.7	17.1%	31.5	Increase by consolidation of Ranbaxy, etc.
Buildings and structures	136.8		138.0		1.1	
Machinery, equipment and vehicles	33.2		49.7		16.5	
Land	33.1		35.0		1.9	
Construction in progress	2.9		13.2		10.2	
Other	15.2		16.9		1.7	
Intangible assets	91.1	6.1%	192.4	13.0%	101.3	
Goodwill, net	15.4		115.4		100.0	U3 Pharma AG: ¥ +25.1 billion (Amortization period: five years from 2Q of FY2008) Ranbaxy: ¥ +80.0 billion <Reference>: Goodwill ¥439.5 billion (Amortization period: 20 years from 3Q of FY2008) Amortization of goodwill ¥5.5 billion One-time write-off ¥354.0 billion
Other intangible assets, net	75.7		77.0		1.3	
Investments and other assets	249.0	16.7%	210.8	14.2%	-38.3	
Investment securities	216.0		175.2		-40.9	Decrease of market value due to stagnation in equity market
Long-term loans	1.3		1.1		-0.2	
Prepaid pension costs	8.0		7.0		-1.0	
Deferred tax assets	6.0		10.7		4.7	
Other assets	18.0		17.1		-1.0	
Allowance for doubtful accounts	-0.4		-0.3		0.0	
<b>Total assets</b>	<b>1,487.9</b>	<b>100.0%</b>	<b>1,479.7</b>	<b>100.0%</b>	<b>-8.2</b>	

## &lt;Liabilities and Net Assets&gt;

(Billions of yen)

	2008.3.31		2008.12.31		Change	Details
		%		%		
<b>Liabilities</b>	<b>243.4</b>	<b>16.4%</b>	<b>654.0</b>	<b>44.2%</b>	<b>410.7</b>	
Current liabilities	194.5	13.1%	544.8	36.8%	350.3	
Trade notes and accounts payable	46.4		66.2		19.8	
Short-term bank loans	0.1		316.5		316.5	..... Borrowings for the acquisition of Ranbaxy's share <u>¥+240.0 billion</u> Increase by consolidation of Ranbaxy
Income taxes payable	18.7		9.9		-8.8	
Allowance for sales returns	0.8		0.9		0.1	
Allowance for sales rebates	0.8		1.3		0.6	
Allowance for contingent losses	0.2		0.4		0.2	
Other current liabilities	127.6		149.6		22.0	..... Increase by consolidation of Ranbaxy
Non-current liabilities	48.9	3.3%	109.3	7.4%	60.4	
Convertible bond-type bonds with subscription rights to shares	-		46.5		46.5	..... Increase by consolidation of Ranbaxy
Long-term bank loans	0.0		16.7		16.6	..... Increase by consolidation of Ranbaxy
Deferred tax liabilities	26.7		13.4		-13.3	
Accrued employees' severance and retirement benefits	6.8		10.7		3.9	
Accrued directors' and corporate auditors' severance and retirement	0.1		0.2		0.0	
Provision for environmental measures	1.1		0.3		-0.8	
Other non-current liabilities	14.2		21.6		7.4	
<b>Net assets</b>	<b>1,244.5</b>	<b>83.6%</b>	<b>825.6</b>	<b>55.8%</b>	<b>-418.9</b>	
Shareholders' equity	1,211.6	81.4%	812.1	54.9%	-399.5	
Common stock	50.0		50.0		0.0	
Capital surplus	179.9		105.2		-74.7	..... Cancellation of treasury stock <u>¥-74.7 billion</u> (26 million shares)
Retained earnings	1,025.1		671.5		-353.7	..... One-time write-down on goodwill of Ranbaxy <u>¥-354.0 billion</u>
Treasury stock at cost	-43.4		-14.5		28.9	..... Share buyback: 15 million shares, <u>¥-45.7 billion</u> Cancellation: 26 million shares, <u>¥+74.7 billion</u>
Valuation and other adjustments	32.3	2.2%	-16.2	-1.1%	-48.5	
Net unrealized gain on investment securities	48.5		29.6		-19.0	..... Decrease due to stagnation in equity market
Foreign currency translation adjustments	-16.3		-45.8		-29.5	
Subscription rights to shares	0.3	0.0%	0.6	0.0%	0.4	
Minority interests	0.4	0.0%	29.1	2.0%	28.7	
<b>Total liabilities and net assets</b>	<b>1,487.9</b>	<b>100.0%</b>	<b>1,479.7</b>	<b>100.0%</b>	<b>-8.2</b>	

## 10. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2007 1-3Q	FY2008 1-3Q	Change	Details
Income/Loss before income taxes and minority interests	161.2	-265.4	-426.6	
Depreciation	28.6	28.4	-0.2	
Loss on impairment of property, plant and equipment	-	2.2	2.2	
Amortization of goodwill	2.7	10.5	7.8	U3 Pharma AG: ¥+2.5billion (2-3Q) Ranbaxy: ¥+5.5billion (3Q)
One-time write-down of goodwill	-	354.0	354.0	One-time write-down of Ranbaxy goodwill
Increase (decrease) in accrued severance and retirement benefits	-24.5	0.5	25.0	
(Increase) decrease in prepaid pension costs	12.0	1.0	-11.0	
(Increase) decrease in trade notes and accounts receivable	-37.0	-40.0	-3.0	
(Increase) decrease in inventories	-5.3	-2.1	3.2	
Increase (decrease) in trade notes and accounts payable	8.1	4.4	-3.7	
Increase (decrease) in accounts payable and accrued expense	-68.7	-16.1	52.5	FY2007 Payment of accrued severance and retirement benefits due to workforce resizing and employment transfer to function-based subsidiaries, etc
Other, net	-1.7	1.2	2.9	
Income taxes paid	-52.5	-51.5	1.0	
<b>I. Cash flows from operating activities</b>	<b>22.9</b>	<b>27.1</b>	<b>4.2</b>	
Net decrease (increase) in short-term operating assets	-16.9	49.2	66.1	Decrease in investment activity
Acquisition/sales of fixed assets	-19.1	-30.5	-11.4	Acquisition of the right to expand marketing area of Evista
Acquisition/sales of investment securities	3.9	-11.0	-14.9	
Net decrease (increase) in loans receivable	8.7	0.4	-8.3	
Proceeds from sale of investments in consolidated subsidiaries	8.8	0.0	-8.8	
Purchases of investments in consolidated subsidiaries resulting in changes in scope of consolidation	-	-408.4	-408.4	Acquisition of Ranbaxy : ¥384.1 billion Acquisition of U3 Pharma AG: ¥24.3 billion
Other, net	-	4.4	4.4	
<b>II. Cash flows from investment activities</b>	<b>-14.7</b>	<b>-395.8</b>	<b>-381.2</b>	
Net increase (decrease) in short-term bank loans	-4.6	239.9	244.6	Borrowings for the acquisition of Ranbaxy's share: ¥240.0 billion
Purchases of treasury stock	-33.4	-45.8	-12.4	FY2008:Acquired 15 million shares for ¥45.7 billion FY2007:Acquired 10 million shares for ¥33.2 billion
Dividends paid	-47.1	-53.3	-6.2	Dividend increase of 5 yen per share
Other, net	0.0	0.0	0.0	
<b>III. Cash flows from financing activities</b>	<b>-85.2</b>	<b>140.8</b>	<b>226.0</b>	
<b>IV. Effect of exchange rate changes on cash and cash equivalents</b>	<b>-0.4</b>	<b>-10.7</b>	<b>-10.3</b>	
<b>V. Net increase (decrease) in cash and cash equivalents</b>	<b>-77.3</b>	<b>-238.7</b>	<b>-161.3</b>	
<b>VI. Cash and cash equivalents, beginning of period</b>	<b>513.2</b>	<b>444.3</b>	<b>-68.9</b>	
<b>VII. Increase (decrease) in cash and cash equivalents due to changes in scope of consolidation</b>	<b>0.5</b>	<b>-</b>	<b>-0.5</b>	
<b>VIII. Increase in cash and cash equivalents due to merger with unconsolidated subsidiaries</b>	<b>1.0</b>	<b>-</b>	<b>-1.0</b>	
<b>IX. Cash and cash equivalents, end of year</b>	<b>437.4</b>	<b>205.7</b>	<b>-231.7</b>	

# Major R&D Pipeline

## Daiichi Sankyo Group Major Research & Development Pipeline (Development Stage)

January 2009  
DAIICHI SANKYO CO., LTD.

Therapeutic Area	Main Existing Product	Phase1	Phase2	Phase3	Application
Cardiovascular diseases	Mevalotin Benicar/Olmetec Azor Welchol  Olmetec Calblock Artist Mevalotin Kremezin Hanp Livalo Sunrythm Bepricor	DB-772d(US/EU) (oral factor Xa inhibitor)  <del>CS-8080(US/EU)</del> (anti-arteriosclerosis)	★CS-866CMB(JP) (Olmesartan Medoxomil/Hydrochlorothiazide combination)  CS-747(JP) (Prasugrel/anti-platelet agent)	★CS-747(US/EU) (Prasugrel/ACS-MM/anti-platelet agent)  ★CS-866DM(JP) (Olmesartan Medoxomil/diabetic nephropathy)  DU-176b(US/EU/JP) (oral factor Xa inhibitor)  ★CS-8635(US) (Olmesartan Medoxomil/Amlodipine Besilate/Hydrochlorothiazide combination)	CS-747(US/EU) (Prasugrel/ACS-PCI/anti-platelet agent)  ★CS-8663(EU) (Olmesartan Medoxomil/Amlodipine Besilate combination/ approved/launched)  ★CS-866AZ(JP) (Olmesartan Medoxomil/Azelnidipine combination)
Glucose metabolic disorders	Welchol Fastic	CS-1036(JP) (glucose absorption inhibitor)	CS-011(JP) (Rivoglitazone/ glitazone agent that improves insulin resistance)	CS-011(US/EU) (Rivoglitazone/ glitazone agent that improves insulin resistance)	
Infectious diseases	Levaquin / Tavanic Banan Cravit	CS-8958(US/EU) (anti-influenza/co-development with Biota)		★levofloxacin inj(JP) (new quinolone)  CS-8958(JP) (anti-influenza)	★levofloxacin high-dose(JP) (new quinolone)
Cancer	Topotecin Krestin	U3-1287(US) (anti-HER3 antibody)	CS-1008(US) (anti-DR5 antibody)  CS-7017(US) (PPAR $\gamma$ activator)  DE-766(JP) (Nimotuzumab/anti-EGFR antibody)  <u>ARQ197(US/EU)</u> (c-Met inhibitor)		
Immunological allergic diseases	Zyrtec	CS-0777(US/EU) (immunomodulator)	SUN13834(US) (Chymase inhibitor)		
Bone/Joint diseases	Loxonin Mobic			AMG 162(JP) (Denosumab/ anti-RANKL antibody/ bone metastases of cancer, osteoporosis)  ★CS-600G(JP) (Loxoprofen Sodium/gel)	
Others	Venofer Evoxac  Omnipaque Omniscan Feron Urief		SUN11031(JP) (Human ghrelin/anorexia nervosa)  SUN11031(US/EU) (Human ghrelin/cachexia)	SUN Y7017(JP) (Memantine Hydrochloride/ mild to moderate and severe dementia of Alzheimer type)	★DL-8234(JP) (FERON add indic./hepatitis C/with Ribavirin)  KMD-3213(China) (Sildenafil/treatment of dysuria associated with benign prostatic hyperplasia)

★additional indications, new formulations etc.

Change from the announcement of October 2008

- # New(underline) : ARQ197 (US/EU)
- # Change of Stage etc. : CS-8663 (EU) 、 CS-866AZ (JP) 、 KMD-3213 (China) 、 DU-176b (US/EU/JP) 、 CS-8958 (JP) 、 CS-7017 (US)
- # Withdrawal of Development etc. : CS-0808(US/EU)[DAIICHI SANKYO Group withdrew from this project because it did not satisfy the expected criteria in clinical trials.]

Sales tie-up, License activity etc.

	Phase1	Phase2	Phase3	Application
	HGF DNA therapy(US/EU) (coronary arterial diseases/ sales agreement) SUN N8075(US/EU)(neuroprotectant/ licensed-out to Cecoura )	HGF DNA therapy(US/EU)(peripheral arterial diseases/ sales agreement) SUN N4057(US/EU)(Serotonin 1A receptor agonist) <del>CS-088(US/EU/JP)(Olmesartan/antiglaucoma/ co-development with Santen)</del>		DF-098(JP)(ActHIB/sales agreement/approved/launched) HGF DNA therapy(JP)(Collatogene/peripheral arterial diseases/sales agreement) SUN 0588r(EU)(Sapropterin Hydrochloride/hyperphenylalaninemia/ licensed-out to BioMarin/approved)

CS-088: Santen and DAIICHI SANKYO Group withdrew from this project because it was recognized that it is difficult to satisfy an expected criteria as a result of clinical trials.

# <Historical Data>

## 1. Summary of Income Statement

(Billions of yen)

	FY2007							
	2Q		3Q		4Q		Full Year	
	<-3.3>		<-3.0>		<-7.3>		<-5.3>	
Net sales	100.0	208.2	100.0	252.1	100.0	184.3	100.0	880.1
Cost of sales	26.6	55.3	27.2	68.5	28.7	52.8	26.7	234.6
Selling, general and administrative expenses	60.9	126.7	47.9	120.7	71.3	131.4	55.5	488.7
Research and development expenses	21.9	45.5	15.4	38.8	25.2	46.5	18.6	163.5
Other expenses	39.0	81.2	32.5	82.0	46.1	84.9	37.0	325.2
Operating income	<48.5>	<26.1>	<17.2>	<62.9>	<0.0>	<0.1>	<17.8>	<156.8>
Non-operating income		2.8		3.5		4.8		17.0
Non-operating expenses		-0.2		1.0		1.9		4.8
Ordinary income	<42.6>	<29.0>	<12.8>	<65.4>	<1.6>	<3.0>	<19.2>	<169.1>
Extraordinary gains		0.1		0.1		12.0		16.1
Extraordinary losses		2.6		2.3		9.4		18.3
Income before income taxes and minority interests	12.7	26.5	25.1	63.2	3.1	5.7	19.0	166.9
Net income	<-0.3>	<18.8>	<14.3>	<36.2>	<0.7>	<1.2>	<11.1>	<97.7>

	FY2008							
	1Q		2Q		3Q		3Q YTD	
	<-13.5>		<-2.7>		<-12.2>		<-9.8>	
Net sales	100.0	203.7	100.0	202.6	100.0	221.3	100.0	627.6
Cost of sales	23.9	48.6	24.2	49.0	24.0	53.1	24.0	150.8
Selling, general and administrative expenses	56.5	115.1	65.1	132.0	59.5	131.7	60.4	378.8
Research and development expenses	18.1	36.9	22.4	45.4	21.2	46.8	20.6	129.2
Other expenses	38.4	78.2	42.7	86.6	38.4	84.9	39.8	249.6
Operating income	<-41.0>	<40.0>	<-17.1>	<21.6>	<-42.0>	<36.4>	<15.6>	<98.1>
Non-operating income		3.6		2.5		3.0		9.2
Non-operating expenses		2.8		5.3		5.9		14.0
Ordinary income	<-43.0>	<40.9>	<-35.3>	<18.8>	<-48.7>	<33.5>	<-43.9>	<93.2>
Extraordinary gains		0.0		0.8		1.8		2.7
Extraordinary losses		1.3		2.6		357.4		361.3
Income before income taxes and minority interests	19.4	39.5	8.4	17.0	-	-322.0	-	-265.4
Net income	<-39.4>	<25.1>	<-52.8>	<8.9>	<->	<-331.8>	<->	<-297.8>

## <Performance excluding the effects of changes in fiscal year-end of the U.S./European subsidiaries and non-pharmaceutical business>

(Billions of yen)

	FY2007							
	2Q		3Q		4Q		Full Year	
	<6.5>		<7.7>		<3.2>		<5.1>	
Net sales	100.0	199.9	100.0	243.1	100.0	177.7	100.0	834.0
Cost of sales	23.9	47.8	24.9	60.5	26.8	47.6	24.3	203.0
Selling, general and administrative expenses	62.8	125.5	49.2	119.6	73.6	130.8	57.1	475.8
Research and development expenses	22.7	45.3	15.9	38.5	26.1	46.4	19.5	162.4
Other expenses	40.1	80.2	33.3	81.1	47.5	84.4	37.6	313.5
Operating income	<69.3>	<26.6>	<19.8>	<63.0>	<-0.4>	<-0.7>	<18.6>	<155.1>
Non-operating income		2.8		3.5		4.8		16.6
Non-operating expenses		-0.2		1.0		1.8		4.7
Ordinary income	<58.4>	<29.5>	<15.4>	<65.5>	<1.3>	<2.3>	<20.0>	<167.1>
Extraordinary gains		0.1		0.1		5.0		7.4
Extraordinary losses		2.6		2.3		7.9		16.9
Income before income taxes and minority interests	13.5	27.0	26.1	63.4	-0.4	-0.7	18.9	157.6
Net income	<28.4>	<19.2>	<15.9>	<38.7>	<-0.5>	<-0.9>	<11.4>	<95.1>

	FY2008							
	1Q		2Q		3Q		3Q YTD	
	<-4.5>		<-1.4>		<-9.0>		<-4.4>	
Net sales	100.0	203.7	100.0	202.6	100.0	221.3	100.0	627.6
Cost of sales	23.9	48.6	24.2	49.0	24.0	53.1	24.0	150.8
Selling, general and administrative expenses	56.5	115.1	65.1	132.0	57.0	126.2	59.5	373.3
Research and development expenses	18.1	36.9	22.4	45.4	21.2	46.8	20.6	129.2
Other expenses	38.4	78.2	42.7	86.6	35.9	79.4	38.9	244.1
Operating income	<-39.5>	<40.0>	<-18.7>	<21.6>	<-33.5>	<41.9>	<16.5>	<103.5>
Non-operating income		3.6		2.5		3.0		9.2
Non-operating expenses		2.8		5.3		5.9		14.0
Ordinary income	<-41.4>	<40.9>	<-36.4>	<18.8>	<-40.4>	<39.0>	<-40.1>	<98.7>
Extraordinary gains		0.0		0.8		1.8		2.7
Extraordinary losses		1.3		2.6		3.4		7.3
Income before income taxes and minority interests	19.4	39.5	8.4	17.0	16.9	37.5	15.0	94.1
Net income	<-34.2>	<25.1>	<-53.6>	<8.9>	<-28.5>	<27.7>	<-9.8>	<61.7>

## 2. Sales of Global Products

(Billions of yen)

	FY2007							
	2Q		3Q		4Q		Full Year	
	<33.1>		<35.8>		<22.8>		<22.0>	
Olmesartan	43.6	54.0	44.9	195.6				
Olmotec (JPN)	<31.4>	12.6	<29.5>	17.6	<21.4>	11.2	<30.7>	55.2
Benicar / Benicar HCT (US)	<23.0>	21.7	<22.0>	24.1	<-2.0>	19.3	<-5.3>	87.9
Azor (US)		-	<>	1.9	<>	0.7	<>	2.5
Olmotec / Olmetec Plus* (EU)	<52.4>	7.4	<45.0>	8.3	<66.5>	11.2	<85.6>	41.8
Sevikar (EU)		-		-		-		-
Export / Asian & LA subsidiaries, etc	<184.6>	1.9	<199.0>	2.1	<180.7>	2.5	<189.2>	8.1
Levofloxacin	<-1.6>	23.5	<-1.0>	32.1	<-3.6>	23.7	<-4.4>	108.7
Cravit (JPN)	<7.2>	10.0	<-8.5>	15.5	<11.5>	9.8	<-1.4>	47.4
Export, etc	<-20.0>	6.9	<13.2>	9.7	<-5.5>	6.6	<-6.8>	34.0
Royalty	<8.6>	4.6	<-6.9>	4.8	<3.0>	5.4	<2.8>	19.5
Asian subsidiaries	<20.7>	1.9	<19.6>	2.1	<2.9>	1.9	<19.5>	7.8
Pravastatin	<-28.6>	18.6	<-12.3>	21.6	<-14.1>	14.5	<-18.3>	76.5
Mevalotin (JPN)	<-9.6>	15.4	<-8.7>	18.2	<-10.3>	11.6	<-9.1>	61.6
Export	<-83.7>	1.2	<-54.7>	1.4	<-68.2>	0.7	<-73.4>	5.0
European subsidiaries*	<-22.8>	1.3	<-13.3>	1.2	<1.5>	1.3	<11.5>	6.7
Asian & LA subsidiaries	<210.4>	0.8	<224.0>	0.8	<212.7>	0.8	<227.5>	3.2

	FY2008							
	1Q		2Q		3Q		3Q YTD	
	<-4.5>		<-23.7>		<6.6>		<7.6>	
Olmesartan	50.7	53.9	57.6	162.2				
Olmotec (JPN)	<12.8>	15.6	<24.9>	15.7	<6.0>	18.7	<13.6>	50.0
Benicar / Benicar HCT (US)	<2.6>	23.4	<1.8>	22.1	<-7.5>	22.3	<-1.2>	67.8
Azor (US)	<>	<>	<>	<39.6>	<>	<240.3>	<>	6.4
Olmotec / Olmetec Plus* (EU)	<-44.3>	8.3	<40.7>	10.3	<10.1>	9.1	<-9.1>	27.8
Sevikar (EU)		-		-		1.4	<>	1.4
Export / Asian & LA subsidiaries, etc	<30.4>	2.0	<72.2>	3.3	<62.0>	3.5	<56.8>	8.8
Levofloxacin	<-12.6>	25.8	<-0.5>	23.6	<-19.8>	25.8	<-11.7>	75.1
Cravit (JPN)	<-15.5>	10.2	<-6.0>	9.4	<11.5>	13.7	<-11.3>	33.3
Export, etc	<-11.3>	9.6	<19.4>	8.3	<-36.8>	6.2	<-12.6>	24.0
Royalty	<-12.6>	4.1	<-13.8>	4.0	<-15.9>	4.1	<-14.2>	12.1
Asian subsidiaries	<-1.8>	1.9	<0.9>	1.9	<11.9>	1.8	<-4.5>	5.7
Pravastatin	<-25.8>	16.1	<-14.9>	15.9	<-23.3>	16.6	<-21.7>	48.5
Mevalotin (JPN)	<-17.1>	13.5	<-14.8>	13.1	<-22.6>	14.1	<-18.4>	40.7
Export	<-39.0>	1.0	<-33.6>	0.8	<-54.0>	0.6	<-42.4>	2.5
European subsidiaries*	<-74.3>	0.7	<-3.4>	1.2	<1.2>	1.2	<-39.9>	3.2
Asian & LA subsidiaries	<-3.1>	0.8	<-7.6>	0.8	<25.4>	0.6	<-12.0>	2.1

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.

Three months results of Olmetec / Olmetec Plus and Pravastatin from Jan-07 to Mar-07 were ¥6.4 billion (€40 million) and ¥1.6 billion (€10 million), respectively.



#### 4. Overseas Sales

(Billions of yen)

	FY2007				FY2008			
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD
Overseas sales	<4.4>	<14.2>	<-4.2>	<0.5>	<-15.9>	<3.6>	<-9.3>	<-8.0>
	83.0	92.4	77.8	358.6	88.7	86.1	83.8	258.5
Overseas sales ratio	39.9%	36.6%	42.2%	40.7%	43.5%	42.5%	37.9%	41.2%
North America	<0.5>	<15.0>	<-11.9>	<-9.1>	<3.9>	<-2.7>	<-15.1>	<-5.0>
	55.1	62.2	46.5	219.9	58.3	53.6	52.8	164.7
Europe*	<3.7>	<2.0>	<7.7>	<16.8>	<-42.6>	<31.8>	<12.9>	<-11.2>
	17.7	19.4	22.3	98.5	22.4	23.3	21.9	67.6
Asia / Latin America, etc	<33.2>	<38.3>	<17.0>	<31.9>	<-22.3>	<-10.9>	<-15.4>	<-16.2>
	10.3	10.7	9.0	40.2	8.0	9.2	9.1	26.2

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.  
The net sales of DSE for the period from January to March 2007 was ¥14.1 billion.

#### 5. Consolidated Segment information - Operating Segment

(Billions of yen)

	FY2007				FY2008			
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD
Net Sales	<-3.3>	<3.0>	<-7.3>	<-5.3>	<-13.5>	<-2.7>	<-12.2>	<-9.8>
	208.2	252.1	184.3	880.1	203.7	202.6	221.3	627.6
Pharmaceuticals	<2.2>	<7.0>	<3.1>	<0.4>	<-10.2>	<1.7>	<-8.6>	<-6.0>
	198.2	241.2	175.6	840.8	202.9	201.6	220.5	625.0
Domestic	<4.0>	<2.3>	<1.8>	<0.9>	<-8.2>	<-0.4>	<-9.3>	<-6.3>
	102.0	135.7	87.0	437.3	103.3	101.6	123.2	328.1
Overseas*	<8.9>	<16.2>	<3.2>	<4.3>	<-14.1>	<5.3>	<-6.1>	<-5.7>
	81.5	89.4	78.3	352.5	88.7	85.8	84.0	258.4
OTC drugs	<8.5>	<0.1>	<30.6>	<4.9>	<3.1>	<-5.2>	<-13.2>	<-6.2>
	14.5	15.2	10.8	50.3	10.2	13.8	13.2	37.2
Other	<-53.5>	<-43.4>	<-69.6>	<-57.4>	<-91.5>	<-90.0>	<-93.0>	<-91.5>
	10.0	10.9	8.7	39.3	0.8	1.0	0.8	2.6
Operating income	<48.5>	<17.2>	<-98.8>	<15.0>	<-41.0>	<-17.1>	<-42.0>	<-37.5>
	26.1	62.9	0.1	156.8	40.0	21.6	36.4	98.1
Pharmaceuticals	<56.5>	<18.4>	<-140.5>	<18.5>	<-42.3>	<-18.9>	<-42.5>	<-39.4>
	25.8	62.5	-1.1	155.6	39.4	20.9	35.9	95.0
Other	<->	<->	<->	<->	<->	<->	46	<->
	-0.1	0.3	1.1	1.0	0.5	0.7	0.5	1.7

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.  
The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

#### 6. Consolidated Segment information - Geographic Segment

(Billions of yen)

	FY2007				FY2008			
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD
Net Sales	<-3.3>	<3.0>	<-7.3>	<-5.3>	<-13.5>	<-2.7>	<-12.2>	<-9.8>
	208.2	252.1	184.3	880.1	203.7	202.6	221.3	627.6
Japan	<-11.8>	<-4.1>	<-11.1>	<-10.4>	<-12.6>	<-7.3>	<-15.8>	<-12.2>
	143.5	179.7	123.0	598.1	132.7	133.0	151.4	417.1
North America	<19.1>	<24.7>	<-11.4>	<-7.1>	<12.5>	<1.4>	<-10.0>	<0.8>
	44.6	51.1	37.2	178.0	50.7	45.3	46.0	141.9
Europe*	<18.2>	<21.6>	<28.2>	<46.1>	<-53.1>	<41.9>	<24.8>	<-13.6>
	13.0	14.4	18.2	78.0	15.2	18.5	18.0	51.7
Asia / Latin America, etc	<73.8>	<52.7>	<36.3>	<55.0>	<-16.9>	<-16.3>	<-13.9>	<-15.7>
	7.0	6.9	5.9	26.1	5.2	5.8	5.9	17.0
Operating income	<48.5>	<17.2>	<-98.8>	<15.0>	<-41.0>	<-17.1>	<-42.0>	<-37.5>
	26.1	62.9	0.1	156.8	40.0	21.6	36.4	98.1
Japan		21.9	47.3	-9.5	18.5	8.2	25.5	52.2
North America		9.2	12.5	2.6	16.9	10.9	11.6	39.4
Europe*		-1.1	1.4	5.9	1.2	0.0	0.5	1.8
Asia / Latin America, etc		0.5	0.7	0.4	0.7	0.4	-3.5	-2.4

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.  
The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

## 7. Status of Major Companies

### 7-1. Daiichi Sankyo Co., Ltd.

(Billions of yen)

	FY2007				FY2008			
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD
	<5.0>	<0.7>	<3.5>	<1.6>	<8.8>	<0.9>	<8.9>	<6.5>
<b>Total net sales of ethical pharmaceuticals</b>	<b>100.3</b>	<b>131.9</b>	<b>84.2</b>	<b>427.1</b>	<b>100.9</b>	<b>99.5</b>	<b>120.1</b>	<b>320.5</b>
<b>Cardiovascular disease</b>	<b>58.5</b>	<b>71.8</b>	<b>50.2</b>	<b>244.2</b>	<b>60.0</b>	<b>57.2</b>	<b>65.5</b>	<b>182.7</b>
Olmotec <antihypertensive>	<31.4> 12.6	<29.5> 17.6	<21.4> 11.2	<30.7> 55.2	<12.8> 15.6	<24.9> 15.7	<6.0> 18.7	<13.6> 50.0
Calblock <antihypertensive>	<16.6> 2.3	<10.2> 3.0	<23.1> 2.4	<16.3> 10.2	<19.4> 3.0	<26.9> 2.9	<13.6> 3.4	<19.4> 9.4
Artist <antihypertensive>	<16.3> 5.1	<3.7> 6.0	<16.5> 4.6	<9.6> 21.1	<3.3> 5.7	<4.9> 5.3	<0.5> 6.0	<2.8> 17.0
Mevalotin <antihyperlipidemic agent>	<9.6> 15.4	<8.7> 18.2	<10.3> 11.6	<9.1> 61.6	<17.1> 13.5	<14.8> 13.1	<22.6> 14.1	<18.4> 40.7
Kremezin <treatment for chronic renal failure>	<7.9> 3.1	<1.8> 3.5	<1.8> 2.7	<1.7> 12.4	<3.9> 3.2	<3.9> 3.2	<0.5> 3.5	<2.3> 9.9
Hanp <treatment for acute cardiac failure>	<13.0> 1.9	<1.7> 2.9	<15.5> 2.4	<6.4> 9.8	<7.8> 2.4	<3.2> 1.8	<5.2> 2.8	<5.6> 7.0
Livalo <antihyperlipidemic agent>	<7.5> 1.3	<3.0> 1.6	<10.1> 1.2	<6.3> 5.5	<10.0> 1.5	<13.8> 1.5	<8.1> 1.8	<10.4> 4.7
Sunrhythm <antiarrhythmic agent>	<10.6> 3.0	<2.4> 3.4	<7.5> 2.5	<3.0> 12.1	<4.2> 3.1	<2.9> 2.9	<6.1> 3.2	<4.5> 9.2
Fastic <antidiabetic agent>	<2.9> 1.3	<5.6> 1.5	<4.0> 1.1	<4.0> 5.2	<0.5> 1.3	<0.1> 1.3	<2.9> 1.4	<1.2> 4.0
<b>Infectious diseases / bone and joint diseases / immunological allergic diseases / urology</b>	<b>30.6</b>	<b>45.9</b>	<b>28.7</b>	<b>138.8</b>	<b>30.8</b>	<b>31.9</b>	<b>44.7</b>	<b>107.4</b>
Cravit <synthetic antibacterial agent>	<7.2> 10.0	<8.5> 15.5	<11.5> 9.8	<1.4> 47.4	<15.5> 10.2	<6.0> 9.4	<11.5> 13.7	<11.3> 33.3
Loxonin <anti-inflammatory analgesic>	<16.2> 8.1	<9.0> 9.8	<6.0> 7.4	<8.7> 33.6	<2.2> 8.4	<28.3> 10.4	<17.1> 11.5	<15.9> 30.4
Mobic <anti-inflammatory analgesic>	<3.1> 2.6	<10.6> 2.9	<2.8> 2.0	<4.0> 10.2	<13.1> 2.4	<16.7> 2.1	<23.1> 2.2	<17.7> 6.8
Urief <treatment for dysuria>	<401.8> 1.2	<145.4> 1.7	<168.5> 1.4	<139.3> 5.4	<59.7> 1.8	<45.4> 1.8	<25.9> 2.1	<41.1> 5.7
Zyrtec <antiallergic agent>	<13.8> 1.9	<18.4> 2.7	<0.6> 3.7	<9.5> 10.8	<23.8> 2.0	<16.1> 1.6	<15.6> 2.2	<18.8> 5.8
<b>Contrast agents / cancer / gastric diseases</b>	<b>14.5</b>	<b>17.1</b>	<b>11.7</b>	<b>59.1</b>	<b>12.3</b>	<b>12.5</b>	<b>13.9</b>	<b>38.7</b>
Omnipaque <contrast agent>	<2.4> 7.7	<6.3> 9.2	<12.7> 6.0	<1.2> 31.2	<11.3> 7.3	<5.4> 7.3	<13.2> 8.0	<10.2> 22.6
Topotecin <anticancer agent>	<20.9> 1.5	<4.0> 1.7	<18.8> 1.3	<13.8> 6.2	<0.7> 1.6	<2.1> 1.5	<1.0> 1.7	<0.5> 4.9

### 7-2. Daiichi Sankyo Healthcare Co., Ltd

(Billions of yen)

	FY2007				FY2008			
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD
	<8.5>	<0.1>	<30.6>	<4.9>	<3.1>	<5.2>	<13.2>	<6.2>
<b>Daiichi Sankyo Healthcare Co., Ltd</b>	<b>14.5</b>	<b>15.2</b>	<b>10.8</b>	<b>50.3</b>	<b>10.2</b>	<b>13.8</b>	<b>13.2</b>	<b>37.2</b>
LuLu Series	<8.7> 3.7	<3.4> 3.7	<28.9> 1.5	<0.5> 10.0	<8.7> 1.2	<2.0> 3.6	<4.0> 3.5	<1.4> 8.4
Gaster 10	<13.0> 0.8	<28.9> 1.0	<64.0> 0.8	<3.0> 3.5	<15.5> 0.7	<7.8> 0.9	<2.6> 1.0	<3.5> 2.6
Shin-Sankyo Ichoyaku series	<5.5> 0.7	<39.1> 1.3	<45.4> 0.8	<17.5> 3.5	<7.9> 0.7	<31.2> 0.9	<26.4> 1.0	<3.0> 2.6
Patecs series	<63.1> 0.9	<41.1> 0.7	<63.6> 0.5	<56.6> 3.0	<19.5> 0.8	<9.0> 0.8	<0.0> 0.7	<10.6> 2.3
Transino	<> 1.4	<> 0.7	<> 0.5	<> 2.6	<> 0.7	<62.0> 0.5	<76.9> 0.2	<34.9> 1.4

7-3. Daiichi Sankyo, Inc. (US)

(Billions of yen)

	FY2007				FY2008			
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD
Daiichi Sankyo, Inc. (DSI)	<21.1> 31.9	<35.1> 37.6	<-16.6> 24.2	<-2.7> 126.9	<12.0> 37.2	<-0.6> 31.7	<-13.5> 32.6	<-1.3> 101.4
mil USD	<19.4> 271	<39.6> 330	<-3.6> 234	<-0.4> 1,110	<29.4> 356	<-8.4> 294	<-2.1> 337	<12.6> 986
Benicar / Benicar HCT <antihypertensive>	<23.0> 21.7	<22.0> 24.1	<-2.0> 19.3	<-5.3> 87.9	<2.6> 23.4	<1.8> 22.1	<-7.5> 22.3	<-1.2> 67.8
mil USD	<21.3> 184	<26.3> 212	<11.6> 184	<-3.0> 769	<18.6> 223	<11.3> 205	<-8.7> 230	<12.7> 659
Azor <antihypertensive>	<> -	<> 1.9	<> 0.7	<> 2.5	<> 1.4	<> 2.4	<-39.6> 2.6	<-240.3> 6.4
mil USD	<> -	<> 16	<> 6	<> 22	<> 13	<> 23	<-66.2> 27	<-288.0> 62
Welchol <antihyperlipidemic / type 2 diabetes>	<27.8> 5.6	<29.5> 6.2	<-3.4> 5.1	<-2.1> 22.7	<11.0> 6.4	<-8.8> 6.1	<-6.6> 6.6	<-8.7> 19.2
mil USD	<26.0> 48	<34.1> 55	<-9.6> 49	<0.2> 199	<28.2> 62	<18.9> 57	<-24.7> 68	<-24.0> 186

7-4. Luitpold Pharmaceuticals, Inc. (US)

(Billions of yen)

	FY2007				FY2008			
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD
Luitpold Pharmaceuticals, Inc. (LPI)	<14.3> 12.7	<2.3> 13.5	<0.6> 13.0	<-16.3> 51.1	<13.8> 13.5	<-6.4> 13.5	<-0.5> 13.4	<-6.3> 40.5
mil USD	<12.6> 108	<5.9> 119	<12.9> 122	<-14.3> 447	<31.4> 129	<16.5> 126	<16.9> 139	<21.2> 393
Venofer <treatment for iron deficiency anemia>	<16.5> 8.0	<-3.5> 8.2	<-5.5> 8.1	<-17.6> 31.1	<23.1> 8.3	<-6.4> 8.5	<1.7> 8.3	<-9.6> 25.2
mil USD	<14.6> 68	<-0.3> 72	<-5.7> 76	<-15.6> 272	<42.2> 80	<16.7> 79	<19.5> 86	<25.0> 245

7-5. Daiichi Sankyo Europe GmbH

(Billions of yen)

	FY2007				FY2008			
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD
Daiichi Sankyo Europe GmbH (DSE)	<22.5> 13.0	<26.3> 14.5	<32.8> 18.2	<-51.0> 78.0	<-53.1> 15.2	<42.4> 18.5	<24.2> 18.0	<-13.6> 51.7
mil €	<9.2> 80	<14.7> 88	<27.4> 115	<37.5> 486	<-54.2> 93	<42.5> 114	<53.8> 136	<-7.6> 343
Olmetec / Olmetec Plus <antihypertensive>	<52.4> 7.4	<45.0> 8.3	<66.5> 11.2	<85.6> 41.8	<-44.3> 8.3	<40.7> 10.3	<10.1> 9.1	<-4.6> 29.2
mil €	<35.5> 45	<31.0> 51	<58.4> 71	<69.0> 261	<-45.6> 51	<40.5> 64	<37.5> 70	<2.1> 194
Sevikar <antihypertensive>	<> -	<> -	<> -	<> -	<> -	<> -	<> 1.4	<> 1.4
mil €	<> -	<> -	<> -	<> -	<> -	<> -	<> 9	<> 9
Mevalotin <antihyperlipidemic agent>	<-22.8> 1.3	<-13.3> 1.2	<1.5> 1.3	<11.5> 6.7	<-74.3> 0.7	<-3.4> 1.2	<1.2> 1.2	<-39.9> 3.2
mil €	<-31.5> 8	<-21.4> 7	<-1.2> 8	<1.5> 42	<-74.9> 4	<-3.6> 8	<23.3> 9	<-35.7> 21
Evista <osteoporosis>	<-38.1> 0.7	<62.6> 1.3	<51.5> 1.4	<87.1> 5.2	<71.7> 3.2	<419.7> 3.5	<134.5> 3.0	<153.8> 9.8
mil €	<-45.8> 4	<46.6> 8	<43.6> 9	<70.4> 33	<67.7> 20	<421.3> 22	<195.4> 23	<171.5> 65

\* Following the change in fiscal year-end, FY2007 results for DSE, Olmetec / Olmetec Plus, Mevalotin and Evista are fifteen-months totals from Jan-07 to Mar-08.

Three months results from Jan-07 to Mar-07 were ¥14.1 billion (€89 million), ¥6.4 billion (€40 million), ¥1.6 billion (€10 million), and ¥1.0 billion (€6 million), respectively.

## 7-6. Asia, South and Central America (ASCA)

### 1) Net Sales by Companies

(Billions of yen)

	FY2007				FY2008				
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD	
<b>ASCA Total</b>	<b>5.2</b>	<b>5.2</b>	<b>5.9</b>	<b>21.0</b>	<b>&lt;10.5&gt;</b>	<b>&lt;12.7&gt;</b>	<b>&lt;14.3&gt;</b>	<b>&lt;12.5&gt;</b>	<b>17.0</b>
Daiichi Pharmaceutical (Beijing) Co., Ltd. (DPP)	1.0	1.0	1.2	4.1	<10.9>	<-0.8>	<11.4>	<7.0>	3.1
Shanghai Sankyo Pharmaceuticals Co., Ltd. (SSP)	0.6	0.7	0.5	2.3	<-29.5>	<64.3>	<62.4>	<52.8>	2.7
Daiichi Sankyo Korea Co., Ltd. (DSKR)	0.9	0.9	0.8	3.4	<-4.3>	<1.1>	<-35.5>	<-10.2>	2.4
Daiichi Sankyo (Thailand) Ltd. (DSTH)	0.2	0.2	0.2	0.8	<-4.9>	<17.9>	<-3.3>	<3.5>	0.6
Daiichi Sankyo Taiwan Ltd. (DSTW)	0.9	0.9	0.9	3.7	<1.6>	<1.2>	<-9.0>	<-2.0>	2.7
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	1.0	1.0	1.4	4.4	<11.5>	<14.9>	<38.7>	<22.1>	3.6
Daiichi Sankyo Venezuela, S.A. (DSVE)	0.5	0.5	0.9	2.4	<-21.7>	<12.0>	<40.5>	<24.5>	1.8

### 2) Sales of Major Products

(Billions of yen)

	FY2007				FY2008				
	2Q	3Q	4Q	Full Year	1Q	2Q	3Q	3Q YTD	
Olmesartan	0.9	1.0	1.5	4.2	<69.3>	<110.1>	<98.0>	<94.0>	5.3
Levofloxacin	1.9	2.1	1.9	7.8	<-1.8>	<0.9>	<-11.9>	<-4.5>	5.7
Pravastatin	0.8	0.8	0.8	3.2	<-3.1>	<-7.6>	<-25.4>	<-12.0>	2.1

(This page is intentionally left blank)

